The article “Immunomonitoring of human responses to the rVSV-ZEBOV Ebola Vaccine” was published in Current Opinion in Virology journal with the acknowledgment of the VSV-EBOVAC…
How exactly does our immune system respond to vaccination? In the first study of its kind, scientists from IMI’s VSV-EBOVAC project, studying a promising Ebola…
From 11th -14th September 2017 , Siena, Italy. Organized by the University of Siena and directed by Dr. Sandra Nuti. The advanced course in flow cytometry will be of particular relevance…
The Sao Paulo School of Advanced Sciences on Vaccines will provide participants with a critical and comprehensive view of the state of the art in vaccine research.…
The aim is to promote and foster a younger generation of scientists in the early stages of their career in Europe. The scope of the…
The U.S. Food and Drug Administration announced today the approval of Ervebo, the first FDA-approved vaccine for the prevention of Ebola virus disease (EVD), caused…
Il progetto internazionale è finanziato da Innovative Medicines Initiative (IMI), partnership tra Unione Europea e Federazione Europea delle Industrie e delle Associazioni Farmaceutiche (EFPIA). Source: https://www.panoramasanita.it/2015/01/16/lotta-allebola-parte-da-siena-lo-studio-per-sviluppare-uno-dei-tre-vaccini-giudicati-piu-promettenti-dalloms/
Repubblica_vaccini141117_press-releaseDownload
Une équipe internationale de chercheurs dirigée par la professeure Claire-Anne Siegrist a mis au point ce qu’on appelle désormais “la formule de Genève”. Cette technique…